A.P. Pharma to Raise $53.6 Million in Common Stock Offering
REDWOOD CITY, Calif. -- July 25, 2012
A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today
announced that it has entered into definitive agreements with certain new and
existing institutional investors relating to a private placement of common
stock. In the transaction, the investors have agreed to purchase 102,000,000
shares at $0.525 per share, resulting in gross proceeds of approximately $53.6
million. The transaction is expected to close on or around July 30, 2012,
subject to the satisfaction of customary closing conditions.
“We believe the $53.6 million to be raised will place the Company in a strong
financial position as we approach the commercialization phase with our lead
product, APF530, which we are developing for the prevention of both acute- and
delayed-onset chemotherapy-induced nausea and vomiting,” stated John B.
Whelan, president and chief executive officer. Mr. Whelan continued, “We
recently completed filling our three registration lots and also have reached
agreement with the FDA on our protocol for our human factors validation study,
which we plan to complete shortly. We plan to resubmit our New Drug
Application to the FDA in September 2012.”
Jefferies & Company, Inc. acted as lead placement agent in the Offering. JMP
Securities LLC acted as co-lead placement agent.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.
The securities sold in the private placement have not been registered under
the Securities Act of 1933, as amended, or state securities laws and may not
be offered or sold in the United States absent registration with the
Securities and Exchange Commission (SEC) or an applicable exemption from such
registration requirements. The Company has agreed to file a registration
statement with the SEC registering the resale of the shares of common stock
sold in the private placement.
A.P. Pharma's lead product, APF530, is being developed for the prevention of
both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
One of the most debilitating side effects of cancer chemotherapy, CINV is a
leading cause of premature discontinuation of treatment. There is only one
injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV,
so this indication represents an area of particular unmet medical need. APF530
contains the 5-HT3 antagonist granisetron formulated in the Company’s
proprietary Biochronomer™ drug delivery system, which allows therapeutic drug
levels to be maintained for five days with a single subcutaneous injection.
This five-day range is designed to cover the delayed phase of CINV, whereas
currently available intravenous and oral formulations of granisetron are
approved only for the prevention of acute-onset CINV. Granisetron was selected
for APF530 because it is widely prescribed by physicians based on a
well-established record of safety and efficacy.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company developing products using
its proprietary Biochronomer™ polymer-based drug delivery platform. This drug
delivery platform is designed to improve the therapeutic profile of injectable
pharmaceuticals by converting them from products that must be injected once or
twice per day to products that need to be injected only once every one or two
weeks. The Company’s lead product, APF530, is being developed for the
prevention of both acute- and delayed-onset chemotherapy-induced nausea and
vomiting. A.P. Pharma received a Complete Response Letter to its APF530 New
Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S.
Food and Drug Administration in September 2012. For further information,
please visit the Company's web site at www.appharma.com.
This news release contains "forward-looking statements" as defined by the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements involve risks and uncertainties, including uncertainties associated
with the potential approval of APF530 and the potential timing for such
approval, if approved at all, as well as risks relating to capital resources
and liquidity, satisfactory completion of clinical studies, progress in
research and development programs, launch and acceptance of new products and
other risks and uncertainties identified in the Company's filings with the
Securities and Exchange Commission. We caution investors that forward-looking
statements reflect our analysis only on their stated date. We do not intend to
update them except as required by law.
Investor Relations Contact:
Office Phone: 646-597-6979
A.P. Pharma, Inc.
John B. Whelan, President and Chief Executive Officer
Office Phone: 650-366-2626
Press spacebar to pause and continue. Press esc to stop.